海王生物(000078.SZ)：转让控股子公司股权被动形成对外财务资助

Core Viewpoint - The company, Haiwang Biological, announced a significant change in its corporate structure involving the transfer of 65% equity in Guangxi Haiwang to Zhu Hanhua, resulting in Guangxi Haiwang no longer being a subsidiary within the company's consolidated financial statements [1] Group 1: Equity Transfer - The equity transfer agreement was signed between Guangdong Haiwang Group and Zhu Hanhua, along with a minority shareholder, Longrui (Guangzhou) Biotechnology Co., Ltd [1] - Following the completion of the equity transfer, Guangdong Haiwang Group will no longer hold any shares in Guangxi Haiwang [1] Group 2: Financial Implications - During its existence as a subsidiary, Guangdong Haiwang Group provided operational funding to Guangxi Haiwang, which currently owes Guangdong Haiwang Group a principal loan of 2.7 million yuan and interest [1] - The equity transfer will result in the company continuing to provide financial support to Guangxi Haiwang, which was previously included in the consolidated financial statements [1]